Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the medicare population

Kate V. Viola, Mamta Jhaveri, Pamela R. Soulos, Ryan B. Turner, Whitney L. Tolpinrud, Daven Doshi, Cary P. Gross

Research output: Contribution to journalArticle

Abstract

Objectives: To identify Medicare use rates of Mohs micrographic surgery (MMS) and surgical excision for the treatment of nonmelanoma skin cancer (NMSC) and to identify patient, lesion, and geographic characteristics associated with treatment type. Design:Aretrospective analysis of Medicare beneficiaries. Setting: Surveillance, Epidemiology, and End Results database. Patients: Patients undergoingMMSor other surgical intervention for the treatment of NMSC from January 1, 2001, through December 31, 2006. Main Outcome Measures: Surgical treatment, patient, and lesion characteristics. Results: A total of 26 931 operations were performed for the treatment ofNMSCfrom 2001 through 2006, of which 36.4% were MMS. Although the rate of surgical excision slightly increased during this period (1.8 vs 2.1 per 100 Medicare beneficiaries), the rate of MMS doubled (0.75 vs 1.5 per 100 Medicare beneficiaries). In 46.9% of facial lesions, MMS was performed, whereas MMS was used to treat 14.7% of total body lesions. Atlanta, Georgia, had the highest proportion of patients treated with MMS (45.1%); Louisiana had the lowest (11.0%). Age, race, lesion location, and area of country for patient treatment were significantly associated with MMS use (all P

Original languageEnglish (US)
Pages (from-to)473-477
Number of pages5
JournalArchives of Dermatology
Volume148
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Mohs Surgery
Skin Neoplasms
Medicare
Population
Therapeutics
Epidemiology
Outcome Assessment (Health Care)
Databases

ASJC Scopus subject areas

  • Dermatology

Cite this

Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the medicare population. / Viola, Kate V.; Jhaveri, Mamta; Soulos, Pamela R.; Turner, Ryan B.; Tolpinrud, Whitney L.; Doshi, Daven; Gross, Cary P.

In: Archives of Dermatology, Vol. 148, No. 4, 04.2012, p. 473-477.

Research output: Contribution to journalArticle

Viola, Kate V. ; Jhaveri, Mamta ; Soulos, Pamela R. ; Turner, Ryan B. ; Tolpinrud, Whitney L. ; Doshi, Daven ; Gross, Cary P. / Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the medicare population. In: Archives of Dermatology. 2012 ; Vol. 148, No. 4. pp. 473-477.
@article{4b3a29a11f344303a2206ca9c9fe6a04,
title = "Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the medicare population",
abstract = "Objectives: To identify Medicare use rates of Mohs micrographic surgery (MMS) and surgical excision for the treatment of nonmelanoma skin cancer (NMSC) and to identify patient, lesion, and geographic characteristics associated with treatment type. Design:Aretrospective analysis of Medicare beneficiaries. Setting: Surveillance, Epidemiology, and End Results database. Patients: Patients undergoingMMSor other surgical intervention for the treatment of NMSC from January 1, 2001, through December 31, 2006. Main Outcome Measures: Surgical treatment, patient, and lesion characteristics. Results: A total of 26 931 operations were performed for the treatment ofNMSCfrom 2001 through 2006, of which 36.4{\%} were MMS. Although the rate of surgical excision slightly increased during this period (1.8 vs 2.1 per 100 Medicare beneficiaries), the rate of MMS doubled (0.75 vs 1.5 per 100 Medicare beneficiaries). In 46.9{\%} of facial lesions, MMS was performed, whereas MMS was used to treat 14.7{\%} of total body lesions. Atlanta, Georgia, had the highest proportion of patients treated with MMS (45.1{\%}); Louisiana had the lowest (11.0{\%}). Age, race, lesion location, and area of country for patient treatment were significantly associated with MMS use (all P",
author = "Viola, {Kate V.} and Mamta Jhaveri and Soulos, {Pamela R.} and Turner, {Ryan B.} and Tolpinrud, {Whitney L.} and Daven Doshi and Gross, {Cary P.}",
year = "2012",
month = "4",
doi = "10.1001/archdermatol.2011.2456",
language = "English (US)",
volume = "148",
pages = "473--477",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Mohs micrographic surgery and surgical excision for nonmelanoma skin cancer treatment in the medicare population

AU - Viola, Kate V.

AU - Jhaveri, Mamta

AU - Soulos, Pamela R.

AU - Turner, Ryan B.

AU - Tolpinrud, Whitney L.

AU - Doshi, Daven

AU - Gross, Cary P.

PY - 2012/4

Y1 - 2012/4

N2 - Objectives: To identify Medicare use rates of Mohs micrographic surgery (MMS) and surgical excision for the treatment of nonmelanoma skin cancer (NMSC) and to identify patient, lesion, and geographic characteristics associated with treatment type. Design:Aretrospective analysis of Medicare beneficiaries. Setting: Surveillance, Epidemiology, and End Results database. Patients: Patients undergoingMMSor other surgical intervention for the treatment of NMSC from January 1, 2001, through December 31, 2006. Main Outcome Measures: Surgical treatment, patient, and lesion characteristics. Results: A total of 26 931 operations were performed for the treatment ofNMSCfrom 2001 through 2006, of which 36.4% were MMS. Although the rate of surgical excision slightly increased during this period (1.8 vs 2.1 per 100 Medicare beneficiaries), the rate of MMS doubled (0.75 vs 1.5 per 100 Medicare beneficiaries). In 46.9% of facial lesions, MMS was performed, whereas MMS was used to treat 14.7% of total body lesions. Atlanta, Georgia, had the highest proportion of patients treated with MMS (45.1%); Louisiana had the lowest (11.0%). Age, race, lesion location, and area of country for patient treatment were significantly associated with MMS use (all P

AB - Objectives: To identify Medicare use rates of Mohs micrographic surgery (MMS) and surgical excision for the treatment of nonmelanoma skin cancer (NMSC) and to identify patient, lesion, and geographic characteristics associated with treatment type. Design:Aretrospective analysis of Medicare beneficiaries. Setting: Surveillance, Epidemiology, and End Results database. Patients: Patients undergoingMMSor other surgical intervention for the treatment of NMSC from January 1, 2001, through December 31, 2006. Main Outcome Measures: Surgical treatment, patient, and lesion characteristics. Results: A total of 26 931 operations were performed for the treatment ofNMSCfrom 2001 through 2006, of which 36.4% were MMS. Although the rate of surgical excision slightly increased during this period (1.8 vs 2.1 per 100 Medicare beneficiaries), the rate of MMS doubled (0.75 vs 1.5 per 100 Medicare beneficiaries). In 46.9% of facial lesions, MMS was performed, whereas MMS was used to treat 14.7% of total body lesions. Atlanta, Georgia, had the highest proportion of patients treated with MMS (45.1%); Louisiana had the lowest (11.0%). Age, race, lesion location, and area of country for patient treatment were significantly associated with MMS use (all P

UR - http://www.scopus.com/inward/record.url?scp=84859987903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859987903&partnerID=8YFLogxK

U2 - 10.1001/archdermatol.2011.2456

DO - 10.1001/archdermatol.2011.2456

M3 - Article

C2 - 22508870

AN - SCOPUS:84859987903

VL - 148

SP - 473

EP - 477

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 4

ER -